Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Consensus Price Target from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $17.25.

Several equities research analysts recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Robert W. Baird reduced their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. Finally, HC Wainwright dropped their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th.

Enanta Pharmaceuticals Stock Down 2.7 %

NASDAQ:ENTA opened at $5.85 on Thursday. Enanta Pharmaceuticals has a twelve month low of $5.70 and a twelve month high of $17.80. The firm has a market capitalization of $123.98 million, a price-to-earnings ratio of -1.07 and a beta of 0.49. The stock’s 50 day moving average price is $9.01 and its two-hundred day moving average price is $11.41.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. Enanta Pharmaceuticals’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.33) earnings per share. As a group, analysts anticipate that Enanta Pharmaceuticals will post -4.73 earnings per share for the current year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 13.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors have recently made changes to their positions in ENTA. Allspring Global Investments Holdings LLC acquired a new position in Enanta Pharmaceuticals in the 2nd quarter valued at $35,000. US Bancorp DE raised its holdings in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the 3rd quarter worth $122,000. Quest Partners LLC boosted its stake in Enanta Pharmaceuticals by 511.2% in the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares in the last quarter. Finally, Valence8 US LP bought a new position in Enanta Pharmaceuticals in the third quarter valued at about $207,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.